Basis: FMP quote market capitalization / book value attributable to common shareholders (matching reported total stockholders equity minus preferred stock). Source: stored company filings and market data; unavailable inputs remain N/A.
The P/B ratio is 1.25 as of 2026-10-06T21:37:23.315Z.
Calculation as of: 2026-10-06T21:37:23.315Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 610e9c20fcdf10729c15ba1bd616707a7081826ce2aba31979c935d5001cdfd8
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PB RATIO
1.25
SECTOR MEDIAN · HEALTHCARE
2.39
median of 761 covered companies
CURRENT VS SECTOR MEDIAN
-47.70%
vs the sector median at left
Market Cap
$1.42B
PB Ratio
N/A
TTM Avg
101.84
3Y Avg
52.47
5Y Avg
33.66
Market Cap
$1.45B
PB Ratio
2.80
TTM Avg
2.89
3Y Avg
2.18
5Y Avg
2.32
| NAME | MARKET CAP | PB RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | $1.40B | 1.25 | N/A | N/A | N/A |
| Taysha Gene Therapies, Inc. (TSHA)vs › | $1.40B | 3.63 | 7.79 | 7.53 | 6.36 |
| Braveheart Bio, Inc. (BRVE)vs › | $1.40B | N/A | N/A | N/A | N/A |
| The Pennant Group, Inc. (PNTG)vs › | $1.39B | 3.87 | 3.45 | 3.95 | 3.91 |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 133.96 | 103.22 | 36.11 | 20.51 |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.42B | N/A | 101.84 | 52.47 | 33.66 |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.37B | N/A | 42.62 | 34.40 | 31.48 |
| Certara, Inc. (CERT)vs › | $1.44B | 1.49 | 1.20 | 1.75 | 2.33 |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.45B | 2.80 | 2.89 | 2.18 | 2.32 |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.46B | 3.23 | 4.41 | 3.86 | 3.86 |
P/B Ratio
1.25
Market Price / Book Value per Share
PB Ratio = Market Cap / (Total Shareholders' Equity − Preferred Stock)
The price-to-book ratio compares market capitalization to book value attributable to common shareholders (total equity minus preferred stock). Lower values can indicate a cheaper valuation relative to net assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
